{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:29:16Z","timestamp":1790026156292,"version":"4.0.1"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n The\n A<\/jats:underline>\n ssessing\n W<\/jats:underline>\n orldwide\n A<\/jats:underline>\n ntimicrobial\n R<\/jats:underline>\n esistance\n E<\/jats:underline>\n valuation (AWARE) surveillance program is a sentinel resistance monitoring system designed to track the activity of ceftaroline and comparator agents. In the United States, a total of 8,434 isolates were collected during the 2010 surveillance program from 65 medical centers distributed across the nine census regions (5 to 10 medical centers per region). All organisms were isolated from documented infections, including 3,055 (36.2%) bloodstream infections, 2,282 (27.1%) respiratory tract infections, 1,965 (23.3%) acute bacterial skin and skin structure infections, 665 (7.9%) urinary tract infections, and 467 (5.5%) miscellaneous other infection sites. Ceftaroline was the most potent \u03b2-lactam agent tested against staphylococci. The MIC\n 90<\/jats:sub>\n values were 1 \u03bcg\/ml for methicillin-resistant\n Staphylococcus aureus<\/jats:named-content>\n (MRSA; 98.4% susceptible) and 0.5 \u03bcg\/ml for methicillin-resistant coagulase-negative staphylococci (CoNS). Ceftaroline was 16- to 32-fold more potent than ceftriaxone against methicillin-susceptible staphylococcal strains. All staphylococcus isolates (\n S. aureus<\/jats:named-content>\n and CoNS) were inhibited at ceftaroline MIC values of \u22642 \u03bcg\/ml. Ceftaroline also displayed potent activity against streptococci (MIC\n 90<\/jats:sub>\n , 0.015 \u03bcg\/ml for beta-hemolytic streptococci; MIC\n 90<\/jats:sub>\n , 0.25 \u03bcg\/ml for penicillin-resistant\n Streptococcus pneumoniae<\/jats:named-content>\n ). Potent activity was also shown against Gram-negative pathogens (\n Haemophilus influenzae<\/jats:named-content>\n ,\n Haemophilus parainfluenzae<\/jats:named-content>\n , and\n Moraxella catarrhalis<\/jats:named-content>\n ). Furthermore, wild-type strains of\n Enterobacteriaceae<\/jats:named-content>\n (non-extended-spectrum \u03b2-lactamase [ESBL]-producing strains and non-AmpC-hyperproducing strains) were often susceptible to ceftaroline. Continued monitoring through surveillance networks will allow for the assessment of the evolution of resistance as this new cephalosporin is used more broadly to provide clinicians with up-to-date information to assist in antibiotic stewardship and therapeutic decision making.\n <\/jats:p>","DOI":"10.1128\/aac.00330-12","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T00:58:03Z","timestamp":1333414683000},"page":"2933-2940","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":65,"title":["Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program"],"prefix":"10.1128","volume":"56","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.10.1519172"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.12.019"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq251"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100424"},{"key":"e_1_3_2_7_2","unstructured":"Clinical and Laboratory Standards Institute. 2006. M45-A. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_8_2","unstructured":"Clinical and Laboratory Standards Institute. 2009. M07\u2013A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 8th ed. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_9_2","unstructured":"Clinical and Laboratory Standards Institute. 2011. M100\u2013S21. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq254"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr096"},{"key":"e_1_3_2_12_2","unstructured":"Forest Laboratories Inc. 2010. Teflaro package insert. Forest Laboratories Inc New York NY. http:\/\/www.frx.com\/pi\/Teflaro_pi.pdf."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq108"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01365-08"},{"key":"e_1_3_2_15_2","unstructured":"Infectious Diseases Society of America. 2004. Bad bugs no drugs: as antibiotic discovery stagnates \u2026 a public health crisis brews. Infectious Diseases Society of America Alexandria VA."},{"key":"e_1_3_2_16_2","first-page":"1081","article-title":"The 10 X '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020","volume":"15","author":"Infectious Diseases Society of America","year":"2010","unstructured":"Infectious Diseases Society of America. 2010. The 10 X '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 15:1081\u20131083.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(03)00126-3"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.04.013"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01566-08"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr095"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr097"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/529198"},{"key":"e_1_3_2_24_2","first-page":"5","article-title":"Ceftaroline fosamil (Teflaro)\u2014a new IV cephalosporin","volume":"53","author":"Medical Letter on Drugs and Therapeutics","year":"2011","unstructured":"Medical Letter on Drugs and Therapeutics. 2011. Ceftaroline fosamil (Teflaro)\u2014a new IV cephalosporin. Med. Lett. Drugs Ther. 53:5\u20136.","journal-title":"Med. Lett. Drugs Ther."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01240-09"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-11"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq191"},{"key":"e_1_3_2_28_2","unstructured":"Pfizer. 2010. Tygacil package insert. Pfizer New York NY. http:\/\/www.tygacil.com."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00447-08"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq255"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00330-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00330-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:17:50Z","timestamp":1645463870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00330-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1128\/AAC.00330-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00330-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"2012-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}